SEARCH

SEARCH BY CITATION

References

  • 1
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35, 817.
  • 2
    Shoenfeld Y, Gerli R, Doria A et al. (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21), 333747.
  • 3
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2006) Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 24, 11517.
  • 4
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J (2008) Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 38, 6770.
  • 5
    Kerekes G, Soltesz P, Nurmohamed MT et al. (2012) Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 8, 22434.
  • 6
    Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al. (2003) HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114, 64752.
  • 7
    Vaudo G, Marchesi S, Gerli R et al. (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63, 315.
  • 8
    Hannawi S, Haluska B, Marwick TH, Thomas R (2007) Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 9, R116.
  • 9
    Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA (2009) Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 38, 36671.
  • 10
    Gonzalez-Juanatey C, Llorca J, Andrade AS, Garcia-Porrua C, Martin J, Gonzalez-Gay MA (2006) Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 24, 30912.
  • 11
    Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA (2004) Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum, 51, 44750.
  • 12
    Hurlimann D, Forster A, Noll G et al. (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 21847.
  • 13
    Kerekes G, Soltesz P, Der H et al. (2009) Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 28, 70510.
  • 14
    Del Porto F, Lagana B, Lai S et al. (2007) Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 46, 111115.
  • 15
    Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59, 18214.
  • 16
    Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140, 65962.
  • 17
    Wolfe F, Mitchell DM, Sibley JT et al. (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37, 48194.
  • 18
    Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24, 44551.
  • 19
    Dessein PH, Joffe BI, Veller MG et al. (2005) Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32, 43542.
  • 20
    Del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A (2005) Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 52, 341323.
  • 21
    Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S (1999) Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 26, 256271.
  • 22
    Vita JA, Keaney JF Jr (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106, 6402.
  • 23
    Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H (2002) Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol, 22, 16341.
  • 24
    Hannawi S, Marwick TH, Thomas R (2009) Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 11, R51.
  • 25
    Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5, 57882.
  • 26
    Keystone E, Heijde D, Mason D Jr et al. (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58, 331929.
  • 27
    Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9, 124550.
  • 28
    Keystone EC, Genovese MC, Klareskog L et al. (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68, 78996.
  • 29
    Smolen J, Landewe RB, Mease P et al. (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68, 797804.
  • 30
    Weinblatt ME, Keystone EC, Furst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48, 3545.
  • 31
    Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S (2004) Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 24, 213742.
  • 32
    Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 394, 2003.
  • 33
    Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ (2006) Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26, 112531.
  • 34
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Martin J (2006) Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthrit Rheum 55, 1503.
  • 35
    Ferraccioli G, Bosello S, Santoliquido A et al. (2008) TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27, 8339.
  • 36
    Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ (2005) Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 52, 22939.
  • 37
    Chambless LE, Heiss G, Folsom AR et al. (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146, 48394.
  • 38
    Davis PH, Dawson JD, Riley WA, Lauer RM (2001) Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 104, 281519.
  • 39
    Enderle MD, Schroeder S, Ossen R et al. (1998) Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease. Heart 80, 34954.
  • 40
    Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A (2002) Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 43, 11725.
  • 41
    Hashimoto M, Eto M, Akishita M et al. (1999) Correlation between flow-mediated vasodilation of the brachial artery and intima-media thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol 19, 2795800.
  • 42
    Gonzalez-Juanatey C, Llorca J, Gonzalez-Gay MA (2011) Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther 13, R101.
  • 43
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, Garcia-Porrua C, Testa A, Llorca J (2005) High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32, 121923.
  • 44
    Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD (2011) Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 50, 212539.